Protein intrinsic disorder and human papillomaviruses: Increased amount of disorder in E6 and E7 oncoproteins from high risk HPVs

Journal of Proteome Research

Volumn 5, Issue 8, 2006, Pages 1829-1842

  Uversky, Vladimir N ^a,b,c   Roman, Ann ^a   Oldfield, Christopher J ^a   Dunker, A Keith ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Molecular Kinetics Inc   (United States)

^c INSTITUTE FOR BIOLOGICAL INSTRUMENTATION   (Russian Federation)

Author keywords

Cancer; HPV; Intrinsic protein disorder; Oncoprotein; Papillomavirus; Transforming protein

Indexed keywords

GLYCOPROTEIN E1; PROTEIN E6; PROTEIN E7; VIRUS PROTEIN;

ACETYLATION; ARTICLE; BIOINFORMATICS; CARCINOGENESIS; GENITAL TRACT CANCER; HEAD AND NECK CANCER; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HYDROXYLATION; MOLECULAR RECOGNITION; NONHUMAN; PAPILLOMA; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; SKIN CANCER; UBIQUITINATION; VERRUCA VULGARIS; WART VIRUS;

ALGORITHMS; AMINO ACID SEQUENCE; ANIMALS; COMPUTATIONAL BIOLOGY; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PROTEIN CONFORMATION; PROTEOME; RISK FACTORS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 33747201917     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr0602388     Document Type: Article

References (160)

1. Wright, P. E.; Dyson, H. J. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J. Mol. Biol. 1999, 293, 321-331.
2. Uversky, V. N.; Gillespie, J. R.; Fink, A. L. Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins 2000, 41, 415-427.
3. Dunker, A. K.; Lawson, J. D.; Brown, C. J.; Williams, R. M.; Romero, P.; Oh, J. S.; Oldfield, C. J.; Campen, A. M.; Ratliff, C. M.; Hipps, K. W.; Ausio, J.; Nissen, M. S.; Reeves, R.; Kang, C.; Kissinger, C. R.; Bailey, R. W.; Griswold, M. D.; Chiu, W.; Garner, E. C.; Obradovic, Z. Intrinsically disordered protein. J. Mol. Graph Model 2001, 19, 26-59.
4. Tompa, P. Intrinsically unstructured proteins. Trends Biochem. Sci. 2002, 27, 527-533.
5. Uversky, V. N. Natively unfolded proteins: a point where biology waits for physics. Protein Sci. 2002, 11, 739-756.
6. Uversky, V. N. What does it mean to be natively unfolded? Eur. J. Biochem. 2002, 269, 2-12.
7. Tompa, P. The functional benefits of disorder. J. Mol. Struct. (THEOCHEM) 2003, 666-667, 361-371.
8. Dyson, H. J.; Wright, P. E. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell. Biol. 2005, 6, 197-208.
9. Dunker, A. K.; Obradovic, Z. The protein trinity-linking function and disorder. Nat. Biotechnol. 2001, 19, 805-806.
10. Dunker, A. K.; Brown, C. J.; Obradovic, Z. Identification and functions of usefully disordered proteins. Adv. Protein Chem. 2002, 62, 25-49.
11. Dunker, A. K.; Brown, C. J.; Lawson, J. D.; Iakoucheva, L. M.; Obradovic, Z. Intrinsic disorder and protein function. Biochemistry 2002, 41, 6573-6582.
12. Dunker, A. K.; Cortese, M. S.; Romero, P.; Iakoucheva, L. M.; Uversky, V. N. Flexible nets. The roles of intrinsic disorder in protein interaction networks. FBBS J. 2005, 272, 5129-5148.
13. Uversky, V. N.; Oldfield, C. J.; Dunker, A. K. Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling. J. Mol. Recognit. 2005, 18, 343-384.
14. Dunker, A. K.; Obradovic, Z.; Romero, P.; Garner, E. C.; Brown, C. J. Intrinsic protein disorder in complete genomes. Genome Inform. Ser. Workshop Genome Inform. 2000, 11, 161-171.
15. Ward, J. J.; Sodhi, J. S.; McGuffin, L. J.; Buxton, B. F.; Jones, D. T. Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. J. Mol. Biol. 2004, 337, 635-645.
16. Oldfield, C. J.; Cheng, Y.; Cortese, M. S.; Brown, C. J.; Uversky, V. N.; Dunker, A. K. Comparing and combining predictors of mostly disordered proteins. Biochemistry 2005, 44, 1989-2000.
17. Iakoucheva, L. M.; Brown, C. J.; Lawson, J. D.; Obradovic, Z.; Dunker, A. K. Intrinsic disorder in cell-signaling and cancer-associated proteins. J. Mol. Biol. 2002, 323, 573-584.
18. Lee, H.; Mok, K. H.; Muhandiram, R.; Park, K. H.; Suk, J. E.; Kim, D. H.; Chang, J.; Sung, Y. C.; Choi, K. Y.; Han, K. H. Local structural elements in the mostly unstructured transcriptional activation domain of human p53. J. Biol. Chem. 2000, 275, 29426-29432.
19. Adkins, J. N.; Lumb, K. J. Intrinsic structural disorder and sequence features of the cell cycle inhibitor p57Kip2. Proteins 2002, 46, 1-7.
20. Chang, B. S.; Minn, A. J.; Muchmore, S. W.; Fesik, S. W.; Thompson, C. B. Identification of a novel regulatory domain in Bcl-X(L) and Bcl-2. Embo J. 1997, 16, 968-977.
21. Campbell, K. M.; Terrell, A. R.; Laybourn, P. J.; Lumb, K. J. Intrinsic structural disorder of the C-terminal activation domain from the bZIP transcription factor Fos. Biochemistry 2000, 39, 2708-2713.
22. Mark, W. Y.; Liao, J. C.; Lu, Y.; Ayed, A.; Laister, R.; Szymczyna, B.; Chakrabartty, A.; Arrowsmith, C. H. Characterization of segments from the central region of BRCA1: an intrinsically disordered scaffold for multiple protein-protein and protein-DNA interactions? J. Mol. Biol. 2005, 345, 275-287.
23. Li, X.; Romero, P.; Rani, M.; Dunker, A. K.; Obradovic, Z. Predicting Protein Disorder for N-, C-, and Internal Regions. Genome Inform. Ser. Workshop Genome Inform. 1999, 10, 30-40.
24. Romero, P.; Obradovic, Z.; Li, X.; Garner, E. C.; Brown, C. J.; Dunker, A. K. Sequence complexity of disordered protein. Proteins 2001, 42, 38-48.
25. Liu, J.; Rost, B. NORSp: Predictions of long regions without regular secondary structure. Nucleic Acids Res. 2003, 31, 3833-3835.
26. Linding, R.; Russell, R. B.; Neduva, V.; Gibson, T. J. GlobPlot: Exploring protein sequences for globularity and disorder. Nucleic Acids Res. 2003, 31, 3701-3708.
27. Prilusky, J.; Felder, C. E.; Zeev-Ben-Mordehai, T.; Rydberg, E. H.; Man, O.; Beckmann, J. S.; Silman, I.; Sussman, J. L. FoldIndex: a simple tool to predict whether a given protein sequence is intrinsically unfolded. Bioinformatics 2005, 21, 3435-3438.
28. Dosztanyi, Z.; Csizmok, V.; Tompa, P.; Simon, I. IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics 2005, 21, 3433-3434.
29. Jones, D. T.; Ward, J. J. Prediction of disordered regions in proteins from position specific score matrixes. Proteins 2003, 53 Suppl 6, 573-578.
30. Ward, J. J.; McGuffin, L. J.; Bryson, K.; Buxton, B. F.; Jones, D. T. The DISOPRED server for the prediction of protein disorder. Bioinformatics 2004, 20, 2138-2139.
31. Bracken, C.; Iakoucheva, L. M.; Romero, P. R.; Dunker, A. K. Combining prediction, computation and experiment for the characterization of protein disorder. Curr. Opin. Struct. Biol. 2004, 14, 570-576.
32. Munger, K. The role of human papillomaviruses in human cancers. Front Biosci. 2002, 7, d641-649.
33. Tommasino, M.; Crawford, L. Human papillomavirus E6 and E7: proteins which deregulate the cell cycle. Bioessays 1995, 17, 509-518.
34. zur Hausen, H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2002, 2, 342-350.
35. Longworth, M. S.; Laimins, L. A. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol. Mol. Biol. Rev. 2004, 68, 362-372.
36. Munger, K.; Baldwin, A.; Edwards, K. M.; Hayakawa, H.; Nguyen, C. L.; Owens, M.; Grace, M.; Huh, K. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 2004, 78, 11451-11460.
37. Munoz, N.; Bosch, F. X.; de Sanjose, S.; Herrero, R.; Castellsague, X.; Shah, K. V.; Snijders, P. J.; Meijer, C. J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348, 518-527.
38. Hughes, F. J.; Romanos, M. A. E1 protein of human papillomavirus is a DNA helicase/ATPase. Nucleic Acids Res. 1993, 21, 5817-5823.
39. Ustav, M.; Stenlund, A. Transient replication of BPV-1 requires two viral polypeptides encoded by the E1 and E2 open reading frames. Embo J. 1991, 10, 449-457.
40. Frattini, M. G.; Laimins, L. A. Binding of the human papillomavirus E1 origin-recognition protein is regulated through complex formation with the E2 enhancer-binding protein. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 12398-12402.
41. Mohr, I. J.; Clark, R.; Sun, S.; Androphy, E. J.; MacPherson, P.; Botchan, M. R. Targeting the E1 replication protein to the papillomavirus origin of replication by complex formation with the E2 transactivator. Science 1990, 250, 1694-1699.
42. Cripe, T. P.; Haugen, T. H.; Turk, J. P.; Tabatabai, F.; Schmid, P. G., 3rd; Durst, M.; Gissmann, L.; Roman, A.; Turek, L. P. Transcriptional regulation of the human papillomavirus-16 E6-E7 promoter by a keratinocyte-dependent enhancer, and by viral E2 trans-activator and represser gene products: implications for cervical carcinogenesis. Embo J. 1987, 6, 3745-3753.
43. Gloss, B.; Bernard, H. U.; Seedorf, K.; Hock, G. The upstream regulatory region of the human papilloma virus-16 contains an E2 protein-independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones. Embo J. 1987, 6, 3735-3743.
44. Wilson, R.; Fehrmann, F.; Laimins, L. A. Role of the E1-E4 protein in the differentiation-dependent life cycle of human papillomavirus type 31. J. Virol. 2005, 79, 6732-6740.
45. Brown, D. R.; Kitchin, D.; Qadadri, B.; Neptune, N.; Batteiger, T.; Ermel, A. The human papillomavirus type 11 E1-E4 protein is a transglutaminase 3 substrate and induces abnormalities of the cornified cell envelope. Virology 2006, 345, 290-298.
46. Davy, C. E.; Ayub, M.; Jackson, D. J.; Das, P.; McIntosh, P.; Doorbar, J. HPV16 E1;E4 protein is phosphorylated by Cdk2/cyclin A and relocalizes this complex to the cytoplasm. Virology 2006.
47. Leechanachai, P.; Banks, L.; Moreau, F.; Matlashewski, G. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene 1992, 7, 19-25.
48. Straight, S. W.; Hinkle, P. M.; Jewers, R. J.; McCance, D. J. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J. Virol. 1993, 67, 4521-4532.
49. Fehrmann, F.; Klumpp, D. J.; Laimins, L. A. Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation. J. Virol. 2003, 77, 2819-2831.
50. Genther, S. M.; Sterling, S.; Duensing, S.; Munger, K.; Sattler, C.; Lambert, P. F. Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J. Virol. 2003, 77, 2832-2842.
51. Zhang, B.; Li, P.; Wang, E.; Brahmi, Z.; Dunn, K. W.; Blum, J. S.; Roman, A. The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma. Virology 2003, 310, 100-108.
52. McIntyre, M. C.; Ruesch, M. N.; Laimins, L. A. Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology 1998, 215, 73-82.
53. Massimi, P.; Pim, D.; Banks, L. Human papillomavirus type 16 E7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E7 transforming activity. J. Gen. Virol. 1997, 78 (Pt 10), 2607-2613.
54. Halpern, A. L.; Münger, K. HPV-16E7: Correspondence between primary structure and biological properties, in HPV Sequence Database pp III-58-III-73, Los Alamos National Laboratory, Los Alamos, 1995.
55. Dyson, N.; Howley, P. M.; Munger, K.; Harlow, E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243, 934-937.
56. Zwerschke, W.; Mazurek, S.; Massimi, P.; Banks, L.; Eigenbrodt, E.; Jansen-Durr, P. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 1291-1296.
57. Mazurek, S.; Zwerschke, W.; Jansen-Durr, P.; Eigenbrodt, E. Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex. Biochem. J. 2001, 356, 247-256.
58. Brehm, A.; Nielsen, S. J.; Miska, E. A.; McCance, D. J.; Reid, J. L.; Bannister, A. J.; Kouzarides, T. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. Embo J. 1999, 18, 2449-2458.
59. Tommasino, M.; Adamczewski, J. P.; Carlotti, F.; Barth, C. F.; Manetti, R.; Contomi, M.; Cavalieri, F.; Hunt, T.; Crawford, L. HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin, A. Oncogene 1993, 8, 195-202.
60. Jian, Y.; Schmidt-Grimminger, D. C.; Chien, W. M.; Wu, X.; Broker, T. R.; Chow, L. T. Posttranscriptional induction of p21cip1 protein by human papillomavirus E7 inhibits unscheduled DNA synthesis reactivated in differentiated keratinocytes. Oncogene 1998, 17, 2027-2038.
61. Pim, D.; Massimi, P.; Dilworth, S. M.; Banks, L. Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene 2005, 24, 7830-7838.
62. Brazil, D. P.; Hemmings, B. A. Ten years of protein kinase B signaling: a hard Akt to follow. Trends Biochem. Sci. 2001, 26, 657-664.
63. Gage, J. R.; Meyers, C.; Wettstein, F. O. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J. Virol. 1990, 64, 723-730.
64. Phelps, W. C.; Munger, K.; Yee, C. L.; Barnes, J. A.; Howley, P. M. Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J. Virol. 1992, 66, 2418-2427.
65. McIntyre, M. C.; Frattini, M. G.; Grossman, S. R.; Laimins, L. A. Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. J. Virol. 1993, 67, 3142-3150.
66. Reinstein, E.; Scheffner, M.; Oren, M.; Ciechanover, A.; Schwartz, A. Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue, Oncogene 2000, 19, 5944-5950.
67. Oh, K. J.; Kalinina, A.; Wang, J.; Nakayama, K.; Nakayama, K. I.; Bagchi, S. The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase. J. Virol. 2004, 78, 5338-5346.
68. Armstrong, D. J.; Roman, A. Mutagenesis of human papillomavirus types 6 and 16 E7 open reading frames alters the electrophoretic mobility of the expressed proteins. J. Gen. Virol. 1992, 73 (Pt 5), 1275-1279.
69. Armstrong, D. J.; Roman, A. The anomalous electrophoretic behavior of the human papillomavirus type 16 E7 protein is due to the high content of acidic amino acid residues. Biochem. Biophys. Res. Commun. 1993, 192, 1380-1387.
70. Pahel, G.; Aulabaugh, A.; Short, S. A.; Barnes, J. A.; Painter, G. R.; Ray, P.; Phelps, W. C. Structural and functional characterization of the HPV16 E7 protein expressed in bacteria. J. Biol. Chem. 1993, 265, 26018-26025.
71. Alonso, L. G.; Garcia-Alai, M. M.; Nadra, A. D.; Lapena, A. N.; Almeida, F. L.; Gualfetti, P.; Prat-Gay, G. D. High-risk (HPV16) human papillomavirus E7 oncoprotein is highly stable and extended, with conformational transitions that could explain its multiple cellular binding partners. Biochemistry 2002, 41, 10510-10518.
72. Vousden, K. H.; Doniger, J.; DiPaolo, J. A.; Lowy, D. R. The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Res. 1988, 3, 167-175.
73. Phelps, W. C.; Yee, C. L.; Munger, K.; Howley, P. M. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell. 1888, 53, 539-547.
74. Storey, A.; Pim, D.; Murray, A.; Osborn, K.; Banks, L.; Crawford, L. Comparison of the in vitro transforming activities of human papillomavirus types. Embo J. 1988, 7, 1815-1820.
75. Halbert, C. L.; Demers, G. W.; Galloway, D. A. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol 1991, 65, 473-478.
76. Demers, G. W.; Espling, E.; Harry, J. B.; Etscheid, B. G.; Galloway, D. A. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J. Virol. 1998, 70, 6862-6869.
77. Demers, G. W.; Foster, S. A.; Halbert, C. L.; Galloway, D. A. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4382-4386.
78. Ciccolini, F.; Di Pasquale, G.; Carlotti, F.; Crawford, L.; Tommasino, M. Functional studies of E7 proteins from different HPV types. Oncogene 1994, 9, 2633-2638.
79. Huh, K. W.; DeMasi, J.; Ogawa, H.; Nakatani, Y.; Howley, P. M.; Munger, K. Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. Proc. Nat'l. Acad. Sci. U.S.A. 2005, 102, 11492-11497.
80. Thomas, J. T.; Hubert, W. G.; Ruesch, M. N.; Lalmins, L. A. Human papillomavirus type 31 oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life cycle in normal human keratinocytes. Proc. Nat'l. Acad. Sci. U.S.A. 1999, 96, 8449-8454.
81. Oh, S. T.; Longworth, M. S.; Laimins, L. A. Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. J. Virol. 2004, 78, 2620-2626.
82. Flores, E. R.; Allen-Hoffmann, B. L.; Lee, D.; Lambert, P. F. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J. Virol. 2000, 74, 6622-6631.
83. McLaughlin-Drubin, M. E.; Bromberg-White, J. L.; Meyers, C. The role of the human papillomavirus type 18 E7 oncoprotein during the complete viral life cycle. Virology 2005, 330, 61-68.
84. Zhang, B.; Chen, W.; Roman, A. The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. Proc. Nat'l. Acad. Sci. U.S.A. 2006, 103, 437-442.
85. Scheffner, M.; Werness, B. A.; Huibregtse, J. M.; Levine, A. J.; Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990, 63, 1129-1136.
86. Scheffner, M.; Huibregtse, J. M.; Vierstra, R. D.; Howley, P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993, 75, 495-505.
87. Patel, D.; Huang, S. M.; Baglia, L. A.; McCance, D. J. The E6 protein of human papillomavirus type 16 binds to and inhibits coactivation by CBP and p300. Embo J. 1999, 18, 5061-5072.
88. Zimmermann, H.; Degenkolbe, R.; Bernard, H. U.; O'Connor, M. J. The human papillomavirus type 16 E6 oncoprotein can downregulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 1999, 73, 6209-6219.
89. Kumar, A.; Zhao, Y.; Meng, G.; Zeng, M.; Srinivasan, S.; Delmolino, L. M.; Gao, Q.; Dimri, G.; Weber, G. F.; Wazer, D. E.; Band, H.; Band, V. Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol. Cell. Biol. 2002, 22, 5801-5812.
90. Gross-Mesilaty, S.; Reinstein, E.; Bercovich, B.; Tobias, K. E.; Schwartz, A. L.; Kahana, C.; Ciechanover, A. Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc. Nat'l. Acad. Sci. U.S.A. 1998, 95, 8058-8063.
91. Ronco, L. V.; Karpova, A. Y.; Vidal, M.; Howley, P. M. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 1998, 12, 2061-2072.
92. Kukimoto, I.; Aihara, S.; Yoshiike, K.; Kanda, T. Human papillomavirus oncoprotein E6 binds to the C-terminal region of human minichromosome maintenance 7 protein. Biochem. Biophys. Res. Commun. 1998, 249, 258-262.
93. Srivenugopal, K. S.; Ali-Osman, F. The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein. Oncogene 2002, 21, 5940-5945.
94. Gao, Q.; Kumar, A.; Srinivasan, S.; Singh, L.; Mukai, H.; Ono, Y.; Wazer, D. E.; Band, V. PKN binds and phosphorylates human papillomavirus E6 oncoprotein. J. Biol. Chem. 2000, 275, 14824-14830.
95. Li, S.; Labrecque, S.; Gauzzi, M. C.; Cuddihy, A. R.; Wong, A. H.; Pellegrini, S.; Matlashewski, G. J.; Koromilas, A. E. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 1999, 18, 5727-5737.
96. Gao, Q.; Srinivasan, S.; Boyer, S. N.; Wazer, D. E.; Band, V. The E6 oncoproteins of high-risk papillomaviruses bind to a novel putative GAP protein, E6TP1, and target it for degradation. Mol. Cell. Biol. 1999, 19, 733-744.
97. Filippova, M.; Song, H.; Connolly, J. L.; Dermody, T. S.; Duerksen-Hughes, P. J. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J. Biol. Chem. 2002, 277, 21730-21739.
98. Thomas, M.; Banks, L. Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J. Gen. Virol. 1999, 80 (Pt 6), 1513-1517.
99. Tong, X.; Boll, W.; Kirchhausen, T.; Howley, P. M. Interaction of the bovine papillomavirus E6 protein with the clathrin adaptor complex AP-1. J. Virol. 1998, 72, 476-482.
100. Tong, X.; Howley, P. M. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. Proc. Nat'l. Acad. Sci. U.S.A. 1997, 94, 4412-4417.
101. Chen, J. J.; Reid, C. E.; Band, V.; Androphy, E. J. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science 1995, 269, 529-531.
102. Du, M.; Fan, X.; Hong, E.; Chen, J. J. Interaction of oncogenic papillomavirus E6 proteins with fibulin-1. Biochem. Biophys. Res. Commun. 2002, 296, 962-969.
103. Kiyono, T.; Hiraiwa, A.; Fujita, M.; Hayashi, Y.; Akiyama, T.; Ishibashi, M. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc. Nat'l. Acad. Sci. U.S.A 1997, 94, 11612-11616.
104. Nakagawa, S.; Huibregtse, J. M. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol. Cell. Biol. 2000, 20, 8244-8253.
105. Glaunsinger, B. A.; Lee, S. S.; Thomas, M.; Banks, L.; Javier, R. Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene 2000, 19, 5270-5280.
106. Lee, S. S.; Glaunsinger, B.; Mantovani, F.; Banks, L.; Javier, R. T. Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. J. Virol. 2000, 74, 9680-9693.
107. Sedman, S. A.; Barbosa, M. S.; Vass, W. C.; Hubbert, N. L., Haas, J. A.; Lowy, D. R.; Schiller, J. T. The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture. J. Virol. 1991, 65, 4860-4866.
108. Morosov, A.; Phelps, W. C.; Raychaudhuri, P. Activation of the c-fos gene by the HPV16 oncoproteins depends on the cAMP-response element at -60. J. Biol. Chem. 1994, 269, 18434-18440.
109. Dey, A.; Atcha, I. A.; Bagchi, S. HPV16 E6 oncoprotein stimulates the transforming growth factor-beta 1 promoter in fibroblasts through a specific GC-rich sequence. Virology 1997, 228, 190-199.
110. Gewin, L.; Galloway, D. A. E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. J. Virol. 2001, 75, 7198-7201.
111. Oh, S. T.; Kyo, S.; Laimins, L. A. Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich SpI binding sites. J. Virol. 2001, 75, 5559-5566.
112. Ristriani, T.; Masson, M.; Nomine, Y.; Laurent, C.; Lefevre, J. F.; Weiss, E.; Trave, G. HPV oncoprotein E6 is a structure-dependent DNA-binding protein that recognizes four-way junctions. J. Mol. Biol. 2000, 296, 1189-1203.
113. Ristriani, T.; Nomine, Y.; Masson, M.; Weiss, E.; Trave, G. Specific recognition of four-way DNA junctions by the C-terrninal zinc-binding domain of HPV oncoprotein E6. J. Mol. Biol. 2001, 305, 729-739.
114. Li, X.; Coffino, P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J. Virol. 1996, 70, 4509-4516.
115. Thomas, M. C.; Chiang, C. M. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol. Cell. 2005, 17, 251-264.
116. Nomine, Y.; Charbonnier, S.; Ristriani, T.; Stier, G.; Masson, M.; Cavusoglu, N.; Van Dorsselaer, A.; Weiss, E.; Kieffer, B.; Trave, G. Domain substructure of HPV E6 oncoprotein: biophysical characterization of the E6 C-terminal DNA-binding domain. Biochemistry 2003, 42, 4909-4917.
117. Nomine, Y.; Masson, M.; Charbonnier, S.; Zanier, K.; Ristriani, T.; Deryckere, F.; Sibler, A. P.; Desplancq, D.; Atkinson, R. A.; Weiss, E.; Orfanoudakis, G.; Kieffer, B.; Trave, G. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus- mediated pathogenesis. Mol. Cell. 2006, 21, 665-678.
118. Cole, S. T.; Danos, O. Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. J. Mol. Biol. 1987, 193, 599-608.
119. Pim, D.; Storey, A.; Thomas, M.; Massimi, P.; Banks, L. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene 1994, 9, 1869-1876.
120. Thomas, M.; Pim, D.; Banks, L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999, 18, 7690-7700.
121. Nomine, Y.; Ristriani, T.; Laurent, C.; Lefevre, J. F.; Weiss, E.; Trave, G. Formation of soluble inclusion bodies by hpv e6 oncoprotein fused to maltose-binding protein. Protein Expr. Purif. 2001, 23, 22-32.
122. Hobohm, U.; Scharf, M.; Schneider, R.; Sander, C. Selection of representative protein data sets. Protein Sci. 1992, 1, 409-417.
123. Vihinen, M.; Torkkila, E.; Riikonen, P. Accuracy of protein flexibility predictions. Proteins 1894, 19, 141-149.
124. Peng, K.; Vucetic, S.; Radivojac, P.; Brown, C. J.; Dunker, A. K.; Obradovic, Z. Optimizing long intrinsic disorder predictors with protein evolutionary information. J. Bioinform. Comput. Biol. 2005, 3, 35-60.
125. Obradovic, Z.; Peng, K.; Vucetic, S.; Radivojac, P.; Dunker, A. K. Exploiting heterogeneous sequence properties improves prediction of protein disorder. Proteins 2005, 61 Suppl 7, 176-182.
126. Altschul, S. F.; Madden, T. L.; Schaffer, A. A.; Zhang, J.; Zhang, Z.; Miller, W.; Lipman, D. J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997, 25, 3389-3402.
127. Rost, B.; Sander, C.; Schneider, R. PHD- an automatic mail server for protein secondary structure prediction. Comput. Appl. Biosci. 1994, 10, 53-60.
128. Obradovic, Z.; Peng, K.; Vucetic, S.; Radivojac, P.; Brown, C. J.; Dunker, A. K. Predicting intrinsic disorder from amino acid sequence. Proteins 2003, 53 Suppl 6, 566-572.
129. Kyte, J.; Doolittle, R. F. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 1982, 157, 105-132.
130. Sprent, P. Applied Nonparametric Statistical Methods, 2nd ed.; Chapman and Hall: London, 1993.
131. Dunker, A. K.; Garner, E.; Guilliot, S.; Romero, P.; Albrecht, K.; Hart, J.; Obradovic, Z.; Kissinger, C.; Villafranca, J. E. Protein disorder and the evolution of molecular recognition: theory, predictions and observations. Pac. Symp. Biocomput. 1998, 473-484.
132. Vucetic, S.; Brown, C. J.; Dunker, A. K.; Obradovic, Z. Flavors of protein disorder. Proteins 2003, 52, 573-584.
133. Day, P. M.; Roden, R. B.; Lowy, D. R.; Schiller, J. T. The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. J. Virol. 1998, 72, 142-150.
134. Heino, P.; Zhou, J.; Lambert, P. F. Interaction of the papillomavirus transcription/replication factor, E2, and the viral capsid protein, L2. Virology 2000, 276, 304-314.
135. Goodwin, E. C.; Yang, E.; Lee, C. J.; Lee, H. W.; DiMaio, D.; Hwang, E. S. Rapid induction of senescence in human cervical carcinoma cells. Proc. Nat'l. Acad. Sci. U.S.A. 2000, 97, 10978-10983.
136. zur Hausen, H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Nat'l. Cancer Inst. 2000, 92, 690-698.
137. Hall, A. H.; Alexander, K. A. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J. Virol. 2003, 77, 6066-6069.
138. Desaintes, C.; Demeret, C.; Goyat, S.; Yaniv, M.; Thierry, F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. Embo J. 1997, 16, 504-514.
139. Hawley-Nelson, P.; Vousden, K. H.; Hubbert, N. L.; Lowy, D. R.; Schiller, J. T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. Embo J. 1989, 8, 3905-3910.
140. Munger, K.; Phelps, W. C.; Bubb, V.; Howley, P. M.; Schlegel, R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 1989, 63, 4417-4421.
141. Halbert, C. L.; Demers, G. W.; Galloway, D. A. The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J. Virol. 1992, 66, 2125-2134.
142. Ohlenschlager, O.; Seiboth, T.; Zengerling, H.; Briese, L.; Marchanka, A.; Ramachandran, R.; Baum, M.; Korbas, M.; Meyer-Klaucke, W.; Durst, M.; Gorlach, M. Solution structure of the partially folded high-risk human papilloma virus 45 oncoprotein E7. Oncogene 2006.
143. Liu, X.; Clements, A.; Zhao, K.; Marmorstein, R. Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J. Biol. Chem. 2006, 281, 578-586.
144. Lee, J. O.; Russo, A. A.; Pavletich, N. P. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature (London) 1998, 391, 859-865.
145. Munger, K.; Werness, B. A.; Dyson, N.; Phelps, W. C.; Harlow, E.; Howley, P. M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. Embo J. 1989, 8, 4099-4105.
146. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell. 1995, 81, 323-330.
147. zur Hausen, H. Papillomavirus infections - a major cause of human cancers. Biochim. Biophys. Acta 1996, 1288, F55-78.
148. Hu, Q. J.; Dyson, N.; Harlow, E. The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations. Embo J. 1990, 9, 1147-1155.
149. Kaelin, W. G., Jr.; Ewen, M. E.; Livingston, D. M. Definition of the minimal simian virus 40 large T antigen- and adenovirus E1A-binding domain in the retinoblastoma gene product. Mol. Cell. Biol. 1990, 10, 3761-3769.
150. Huang, S.; Wang, N. P.; Tseng, B. Y.; Lee, W. H.; Lee, E. H. Two distinct and frequently mutated regions of retinoblastoma protein are required for binding to SV40 T antigen. Embo J. 1990, 9, 1815-1822.
151. Lorincz, A. T.; Reid, R.; Jenson, A. B.; Greenberg, M. D.; Lancaster, W.; Kurman, R. J. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet. Gynecol. 1992, 79, 328-337.
152. Van Ranst, M.; Kaplan, J. B.; Burk, R. D. Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations. J. Gen. Virol. 1992, 73 (Pt 10), 2653-2660.
153. Clifford, G. M.; Smith, J. S.; Plummer, M.; Munoz, N.; Franceschi, S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 2003, 88, 63-73.
154. Barbosa, M. S.; Schlegel, R. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 1989, 4, 1529-1532.
155. Burger, R. A.; Monk, B. J.; Kurosaki, T.; Anton-Culver, H.; Vasilev, S. A.; Berman, M. L.; Wilczynski, S. P. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J. Nat'l. Cancer Inst. 1996, 88, 1361-1368.
156. Schwartz, S. M.; Daling, J. R.; Shera, K. A.; Madeleine, M. M.; McKnight, B.; Galloway, D. A.; Porter, P. L.; McDougall, J. K. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J. Clin. Oncol. 2001, 19, 1906-1915.
157. Gross, L. Viral etiology of cancer and leukemia: a look into the past, present and future - G. H. A. Clowes Memorial Lecture. Cancer Res. 1978, 38, 485-493.
158. Cupic, M.; Lazarevic, I.; Kuljic-Kapulica, N. [Oncogenic viruses and their role in tumour formation]. Srp. Arh. Celok. Lek. 2005, 133, 384-387.
159. Gross, L. Oncogenic viruses, 3rd ed.; Pergamon Press: Oxford, 1983.
160. Gross, L. The role of viruses in the etiology of cancer and leukemia in animals and in humans. Proc. Nat'l. Acad. Sci. U.S.A. 1997, 94, 4237-4238.